Lentiviral Vector– tag –
-
ASCO 2026 Highlights CAR-T Cell Therapy Evolution in Multiple Myeloma: Focus on Rapid Manufacturing, Dual-Targeting, and Lentiviral Approaches
YouTube (OncUpdates) USA Overview A YouTube video featuring Dr. Hamza Hashmi discussed the latest advancements in CAR-T therapy for multiple myeloma at ASCO 2026. CAR-T therapy has evolved from a last-resort treatment to a viable option ... -
CDMO Signal Ranks Lentiviral Vector (LVV) CDMOs: GMP Standards and Robust Assays Key for Selection
CDMO Signal USA Overview CDMO Signal published its ranking of Lentiviral Vector (LVV) CDMOs based on Signal Score. LVVs are critical in ex vivo gene therapies for engineering CAR-T cells and modifying hematopoietic stem cells, necessitat... -
Qihan Biotech Receives FDA RMAT and Breakthrough Therapy Designations for Universal Dual-Target CAR-T Therapy, Supported by PackGene Biotech’s CDMO Expertise
PackGene Biotech China Overview Qihan Biotech announced that its universal dual-target CAR-T therapy received both Regenerative Medicine Advanced Therapy (RMAT) and Breakthrough Therapy designations from the U.S. FDA. PackGene Biotech, a... -
Lonza Presents Optimization Strategies to Address Purity and Potency Challenges in In Vivo Lentiviral Vector Development for Cell and Gene Therapies
Biocompare Switzerland Overview Lonza outlined optimization strategies for lentiviral vector (LVV) development for in vivo delivery of cell and gene therapies. Key challenges in LVV development include achieving purity, complexity of val... -
CCRM, OmniaBio, and Avectas Partner to Enhance Cell Therapy Manufacturing with Automated Platform Evaluation
BioSpace Canada Overview CCRM and its CDMO subsidiary, OmniaBio Inc., have partnered with Avectas Limited to evaluate an automated, integrated, and scalable cell therapy manufacturing platform. This collaboration aims to explore how Avec... -
VIVEbiotech Reaches 15 In Vivo Lentiviral Vector Programs, Fortifying Gene Therapy Manufacturing Leadership
BioPharma BoardRoom スペイン Overview VIVEbiotech has significantly advanced its position in gene therapy manufacturing by adding its 15th in vivo lentiviral vector (LVV) therapeutic program. This milestone underscores the company's robu... -
Frontiers Reports GMP-Compliant Scalable Manufacturing Platform Established for Allogeneic Type 1 Regulatory T Cells (TRX103)
Frontiers in Immunology Switzerland Overview A study published in Frontiers reports the establishment of a GMP-compliant, scalable manufacturing platform for TRX103, an allogeneic Type 1 regulatory T cell (Tr1 cell). While TRX103 has sho... -
Lipid Nanoparticles vs. Viral Vectors for Gene Delivery: A Comparative Analysis of Advantages and Applications
Pharma Almanac USA Overview This comparative analysis explores the distinct strengths of lipid nanoparticles (LNPs) and viral vectors in gene delivery. While viral vectors like AAV and lentivirus excel in high-efficiency, durable gene ex... -
VIVEbiotech Scales In Vivo Gene Therapy Portfolio to 15 Programs, Securing Key FDA Clinical Trial Approvals
PharmaSource スペイン Overview Spanish CDMO VIVEbiotech has significantly expanded its in vivo lentiviral vector gene therapy portfolio to 15 programs, several of which have already secured regulatory clearance for clinical trials, inclu... -
ProBio and Curocell Achieve BLA Approval for Next-Gen CD19-Targeted CAR-T Therapy, Initiating Commercial Production in South Korea
ProBio CDMO South Korea Overview ProBio CDMO and Curocell have secured Biologics License Application (BLA) approval for anbalcabtagene autoleucel (Anbal-cel; CRC01), their next-generation CD19-targeted CAR-T cell therapy for relapsed or ...
